A product of independent beta probabilities dose escalation design for dual-agent phase I trials

Statistics in Medicine

Volumn 34, Issue 8, 2015, Pages 1261-1276

  Mander, Adrian P ^a   Sweeting, Michael J ^b  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adaptive design; Dose escalation; Dual agent trial; Nonparametric; Phase I clinical trial

Indexed keywords

ARTICLE; BAYES THEOREM; CANCER RESEARCH; COHORT ANALYSIS; DATA ANALYSIS SOFTWARE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOXICITY; MATHEMATICAL ANALYSIS; MEDICAL LITERATURE; METHODOLOGY; NONPARAMETRIC TEST; PHASE 1 CLINICAL TRIAL (TOPIC); PROBABILITY; RECOMMENDED DRUG DOSE; STATISTICAL ANALYSIS; STATISTICAL MODEL; COMPUTER SIMULATION; DOSE RESPONSE; HUMAN; MAXIMUM TOLERATED DOSE; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOGISTIC MODELS; MAXIMUM TOLERATED DOSE; RESEARCH DESIGN; STATISTICS, NONPARAMETRIC;

EID: 84924434786     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6434     Document Type: Article

References (22)

1. Thall PF, Millikan RE, Mueller P, Lee SJ. Dose-finding with two agents in phase I oncology trials. Biometrics 2003; 59:487-496.
2. Yin G, Yuan Y. Bayesian dose finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2009; 58:211-224.
3. Yin G, Yuan Y. A latent contingency table approach to dose finding for combinations of two agents. Biometrics 2009; 65(3):866-875.
4. Wang K, Ivanova A. Two-dimensional dose finding in discrete dose space. Biometrics 2005; 61(1):217-222.
5. Braun TM, Jia N. A generalized continual reassessment method for two-agent phase I trials. Statistics in Biopharmaceutical Research 2013; 5(2):105-115.
6. Wages NA, Conaway MR, O'Quigley J. Continual reassessment method for partial ordering. Biometrics 2011; 67(4):1555-63.
7. Braun TM, Wang S. A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents. Biometrics 2010; 66(3):805-12.
8. Gasparini M. General classes of multiple binary regression models in dose finding problems for combination therapies. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2013; 62(1):115-133.
9. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Statistics in Medicine 2008; 27(13):2420-2439.
10. Harrington JA, Wheeler GM, Sweeting MJ, Mander AP, Jodrell DI. Adaptive designs for dual-agent phase I dose-escalation studies. Nature Reviews Clinical Oncology 2013; 10(5):277-288.
11. Gasparini M, Eisele J. A curve-free method for phase I clinical trials. Biometrics 2000; 56:609-615.
12. Whitehead J, Thygesen H, Whitehead A. A Bayesian dose-finding procedure for phase I clinical trials based only on the assumption of monotonicity. Statistics in Medicine 2010; 29(17):1808-1824.
13. Ji Y, Li Y, Bekele BN.. Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials 2007; 4(3):235-244.
14. Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clinical Trials 2010; 7(6):653-663.
15. Azriel D, Mandel M, Rinott Y. The treatment versus experimentation dilemma in dose finding studies. Journal of Statistical Planning and Inference 2011; 141(8):2759-2768.
16. Cheung YK. Coherence principles in dose-finding studies. Biometrika 2005; 92(4):863-873.
17. Sweeting MJ, Mander AP. Escalation strategies for combination therapy phase I trials. Pharmaceutical Statistics 2012; (11(3):258-266.
18. Su Z. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities. Contemporary Clinical Trials 2010; 31(1):105-107.
19. Cheung YK. On the use of nonparametric curves in phase I trials with low toxicity tolerance. Biometrics 2002; 58(1):237-240.
20. Bekele BN, Shen Y. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 2005; 61(2):343-354.
21. O'Quigley J, Paoletti X. Continual reassessment method for ordered groups. Biometrics 2003; 59(2):430-440.
22. Ivanova A, Wang K. Bivariate isotonic design for dose-finding with ordered groups. Statistics in Medicine 2006; 25(12):2018-2026.